Plasma acylcarnitines and risk of incident heart failure and atrial fibrillation : the Prevención con dieta mediterránea study
Copyright © 2021 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved..
INTRODUCTION AND OBJECTIVES: Fatty acid metabolic dysregulation in mitochondria is a common mechanism involved in the development of heart failure (HF) and atrial fibrillation (AF). We evaluated the association between plasma acylcarnitine levels and the incidence of HF or AF, and whether the mediterranean diet (MedDiet) may attenuate the association between acylcarnitines and HF or AF risk.
METHODS: Two case-control studies nested within the Prevención con dieta mediterránea (PREDIMED) trial. High cardiovascular risk participants were recruited in Spain: 326 incident HF and 509 AF cases individually matched to 1 to 3 controls. Plasma acylcarnitines were measured with high-throughput liquid chromatography-tandem mass spectrometry. Conditional logistic regression models were fitted to estimate multivariable OR and 95%CI. Additive and multiplicative interactions were assessed by intervention group, obesity (body mass index ≥ 30 kg/m2), and type 2 diabetes.
RESULTS: Elevated levels of medium- and long-chain acylcarnitines were associated with increased HF risk (adjusted ORperDE, 1.28; 95%CI, 1.09-1.51 and adjusted ORperDE, 1.21; 95%CI, 1.04-1.42, respectively). A significant association was observed for AF risk with long-chain acylcarnitines: 1.20 (1.06-1.36). Additive interaction of the association between long-chain acylcarnitines and AF by the MediDiet supplemented with extra virgin olive oil (P for additive interaction=.036) and by obesity (P=.022) was observed in an inverse and direct manner, respectively.
CONCLUSIONS: Among individuals at high cardiovascular risk, elevated long-chain acylcarnitines were associated with a higher risk of incident HF and AF. An intervention with MedDiet+extra-virgin olive oil may reduce AF risk associated with long-chain acylcarnitines. This trial was registered at controlled-trials.com (Identifier: ISRCTN35739639).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Revista espanola de cardiologia (English ed.) - 75(2022), 8 vom: 05. Aug., Seite 649-658 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ruiz-Canela, Miguel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acilcarnitinas |
|---|
| Anmerkungen: |
Date Completed 26.07.2022 Date Revised 02.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rec.2021.10.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334027659 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334027659 | ||
| 003 | DE-627 | ||
| 005 | 20231225222846.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.rec.2021.10.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM334027659 | ||
| 035 | |a (NLM)34866031 | ||
| 035 | |a (PII)S1885-5857(21)00313-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ruiz-Canela, Miguel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma acylcarnitines and risk of incident heart failure and atrial fibrillation |b the Prevención con dieta mediterránea study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2022 | ||
| 500 | |a Date Revised 02.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION AND OBJECTIVES: Fatty acid metabolic dysregulation in mitochondria is a common mechanism involved in the development of heart failure (HF) and atrial fibrillation (AF). We evaluated the association between plasma acylcarnitine levels and the incidence of HF or AF, and whether the mediterranean diet (MedDiet) may attenuate the association between acylcarnitines and HF or AF risk | ||
| 520 | |a METHODS: Two case-control studies nested within the Prevención con dieta mediterránea (PREDIMED) trial. High cardiovascular risk participants were recruited in Spain: 326 incident HF and 509 AF cases individually matched to 1 to 3 controls. Plasma acylcarnitines were measured with high-throughput liquid chromatography-tandem mass spectrometry. Conditional logistic regression models were fitted to estimate multivariable OR and 95%CI. Additive and multiplicative interactions were assessed by intervention group, obesity (body mass index ≥ 30 kg/m2), and type 2 diabetes | ||
| 520 | |a RESULTS: Elevated levels of medium- and long-chain acylcarnitines were associated with increased HF risk (adjusted ORperDE, 1.28; 95%CI, 1.09-1.51 and adjusted ORperDE, 1.21; 95%CI, 1.04-1.42, respectively). A significant association was observed for AF risk with long-chain acylcarnitines: 1.20 (1.06-1.36). Additive interaction of the association between long-chain acylcarnitines and AF by the MediDiet supplemented with extra virgin olive oil (P for additive interaction=.036) and by obesity (P=.022) was observed in an inverse and direct manner, respectively | ||
| 520 | |a CONCLUSIONS: Among individuals at high cardiovascular risk, elevated long-chain acylcarnitines were associated with a higher risk of incident HF and AF. An intervention with MedDiet+extra-virgin olive oil may reduce AF risk associated with long-chain acylcarnitines. This trial was registered at controlled-trials.com (Identifier: ISRCTN35739639) | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acilcarnitinas | |
| 650 | 4 | |a Acylcarnitines | |
| 650 | 4 | |a Atrial fibrillation | |
| 650 | 4 | |a Diet | |
| 650 | 4 | |a Dieta | |
| 650 | 4 | |a Fibrilación auricular | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a Insuficiencia cardiaca | |
| 650 | 7 | |a Olive Oil |2 NLM | |
| 650 | 7 | |a acylcarnitine |2 NLM | |
| 650 | 7 | |a Carnitine |2 NLM | |
| 650 | 7 | |a S7UI8SM58A |2 NLM | |
| 700 | 1 | |a Guasch-Ferré, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Razquin, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Toledo, Estefanía |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Alonso, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Clish, Clary B |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Wittenbecher, Clemens |e verfasserin |4 aut | |
| 700 | 1 | |a Dennis, Courtney |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso-Gómez, Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Almanza-Aguilera, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Liming |e verfasserin |4 aut | |
| 700 | 1 | |a Corella, Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Gracia, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Estruch, Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a Fiol, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Lapetra, José |e verfasserin |4 aut | |
| 700 | 1 | |a Serra-Majem, Lluis |e verfasserin |4 aut | |
| 700 | 1 | |a Ros, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Arós, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Salas-Salvadó, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Frank B |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-González, Miguel Ángel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de cardiologia (English ed.) |d 2010 |g 75(2022), 8 vom: 05. Aug., Seite 649-658 |w (DE-627)NLM206580851 |x 1885-5857 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2022 |g number:8 |g day:05 |g month:08 |g pages:649-658 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rec.2021.10.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2022 |e 8 |b 05 |c 08 |h 649-658 | ||